Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric F Morand

Showing results (181-190 of 226) with videos related to

Pageof 23
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth C Kalunian, Richard Furie, Eric F Morand, et al.
The Lancet. Rheumatology|July 6, 2024
Systemic lupus erythematosus in Aboriginal and Torres Strait Islander peoples in Australia: addressing disparities and barriers to optimising patient careLaura E Eades, Alberta Y Hoi, Ruaidhri Liddle, et al.
Lupus Science & Medicine|August 3, 2023
Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspectiveJoy Buie, Lauren Bloch, Eric F Morand, et al.
Plos One|June 29, 2018
Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patientsCristina M Lanata, Joanne Nititham, Kimberly E Taylor, et al.
Lancet (London, England)|February 27, 2023
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)Eric F Morand, Edward M Vital, Michelle Petri, et al.
Lancet (London, England)|February 27, 2023
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)Michelle Petri, Ian N Bruce, Thomas Dörner, et al.
Annals of the Rheumatic Diseases|November 28, 2015
Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosusSarah A Jones, Andrew E J Toh, Dragana Odobasic, et al.
Frontiers in Immunology|April 23, 2021
GILZ Regulates the Expression of Pro-Inflammatory Cytokines and Protects Against End-Organ Damage in a Model of LupusChampa Nataraja, Wendy Dankers, Jacqueline Flynn, et al.
Pharmacological Research|May 16, 2020
Glucocorticoid-induced leucine zipper modulates macrophage polarization and apoptotic cell clearanceJuliana P Vago, Izabela Galvão, Graziele L Negreiros-Lima, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 25, 2014
Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-α productionYifan Zhan, Emma M Carrington, Hyun-Ja Ko, et al.
Pageof 23

Showing results (181-190 of 226) with videos related to

Sort By:
Pageof 23
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth C Kalunian, Richard Furie, Eric F Morand, et al.
The Lancet. Rheumatology|July 6, 2024
Systemic lupus erythematosus in Aboriginal and Torres Strait Islander peoples in Australia: addressing disparities and barriers to optimising patient careLaura E Eades, Alberta Y Hoi, Ruaidhri Liddle, et al.
Lupus Science & Medicine|August 3, 2023
Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspectiveJoy Buie, Lauren Bloch, Eric F Morand, et al.
Plos One|June 29, 2018
Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patientsCristina M Lanata, Joanne Nititham, Kimberly E Taylor, et al.
Lancet (London, England)|February 27, 2023
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)Eric F Morand, Edward M Vital, Michelle Petri, et al.
Lancet (London, England)|February 27, 2023
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)Michelle Petri, Ian N Bruce, Thomas Dörner, et al.
Annals of the Rheumatic Diseases|November 28, 2015
Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosusSarah A Jones, Andrew E J Toh, Dragana Odobasic, et al.
Frontiers in Immunology|April 23, 2021
GILZ Regulates the Expression of Pro-Inflammatory Cytokines and Protects Against End-Organ Damage in a Model of LupusChampa Nataraja, Wendy Dankers, Jacqueline Flynn, et al.
Pharmacological Research|May 16, 2020
Glucocorticoid-induced leucine zipper modulates macrophage polarization and apoptotic cell clearanceJuliana P Vago, Izabela Galvão, Graziele L Negreiros-Lima, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 25, 2014
Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-α productionYifan Zhan, Emma M Carrington, Hyun-Ja Ko, et al.
Pageof 23